Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

35

Revenue 2017

Symbicort

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Symbicort was produced by AstraZeneca and Astellas.

AZ prepares to file COPD triple, taking on rival GSK

AZ prepares to file COPD triple, taking on rival GSK

It was however unable to show a significant improvement over two other drugs, Symbicort Turbuhaler (budesonide/formoterol fumarate) and PT009 (budesonide/formoterol fumarate).

GSK closes in on EU approval for triple COPD therapy

GSK closes in on EU approval for triple COPD therapy The benefits of Trelegy/Elebrato - delivered using the company's Ellipta dry powder inhaler - are its ability to improve lung function compared to AstraZeneca's ICS/LABA combination Symbicort (budesonide/formoterol)

Smart solutions

Smart solutions It is not just GSK that is under pressure. The likes of AstraZeneca’s Symbicort (budesonide and formoterol), Merck &Co’s Dulera (formoterol and mometasone) and Teva’s Qvar (beclometasone) are

Deal Watch March 2017

Deal Watch March 2017 In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD)

GSK files first application for triple COPD therapy

GSK files first application for triple COPD therapy marketplace. It already has data in hand from the FULFIL trial showing it is more effective than AstraZeneca's Symbicort (formoterol and budesonide).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics